KR900701823A - 혈장단백질의 크로마토그래피 분리법 - Google Patents

혈장단백질의 크로마토그래피 분리법

Info

Publication number
KR900701823A
KR900701823A KR1019900700239A KR900700239A KR900701823A KR 900701823 A KR900701823 A KR 900701823A KR 1019900700239 A KR1019900700239 A KR 1019900700239A KR 900700239 A KR900700239 A KR 900700239A KR 900701823 A KR900701823 A KR 900701823A
Authority
KR
South Korea
Prior art keywords
factor
buffer
concentrate
plasma
fibronectin
Prior art date
Application number
KR1019900700239A
Other languages
English (en)
Other versions
KR970010923B1 (ko
Inventor
띠에리 뷔르누
미리앙 뷔르누
Original Assignee
제이. 제이. 훠르
썽트로 레지오날 드 트랑스퓌지옹 상귄느 드 릴르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9367001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900701823(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제이. 제이. 훠르, 썽트로 레지오날 드 트랑스퓌지옹 상귄느 드 릴르 filed Critical 제이. 제이. 훠르
Publication of KR900701823A publication Critical patent/KR900701823A/ko
Application granted granted Critical
Publication of KR970010923B1 publication Critical patent/KR970010923B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

혈장단백질의 크로마토그래피 분리법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 혈장 저온침전물의 용해성분을 적절한 이온성 음이온 교환수지의 크로마토그래피 단계로 보내어 대형크기의 분자를 유지하고 소수성 상호작용을 일으키며 또한 용리완충액의 이온강도 증가에 따라 각각의 단백질을 선택적으로 회수하는 것을 특징으로 하는 인체 혹은 동물혈장 단백질 분리방법.
  2. 제1항에 있어서, 제 Ⅷ인자, 반 빌레브란드 인자, 피브로겐 및 피브로넥틴을 한유하는 혈장 저온침전물이 초기성분인 것을 특징으로 하는 분리방법.
  3. 제2항에 있어서, 초기성분에 들어있는 제 Ⅷ:C인자의 비활성이 0.1IU/㎎ 이상인 것을 특징으로 하는 방법.
  4. 제1항 내지 3항중 어느항에 있어서, 초기성분에 대하여 : -수산화 알루미늄으로 처리하고,
    -14-16℃로 냉각하며 또한,
    -원심분리하여 나온상청액을 수득하는 것으로된 사전-정제처리 작업을 실행하는 것을 특징으로 하는 방법.
  5. 제1항 내지 4항중 어느 항에 있어서, a) 저온 침전물의 용해성분을 제 Ⅷ인자, 다량의 반 빌레브란드 인자 및 피브로넥틴을 흡수하는 비닐고분자형 겔에 정착된 DEAE 그룹의 수지에 통과시키고 또한 피브리노겐을 용리액속으로 전달하며, b) 완충액의 이온강도를 1차 증가시켜 피브로넥틴 및 다량의 반빌레브란드 인자가 용리되도록 하고 또한, C) 완충액의 이온강도를 또다시 증가시켜 제 Ⅷ인자가 용리되도록 하는 단계를 특징으로 하는 방법.
  6. 제5항에 있어서, 완충액에 리신과 글리신이 들어었는 것을 특징으로 하는 방법.
  7. 제6항에 있어서, 완충액에 2 내지 4g/1의 리신과 8 내지 11g/1의 글리신이 들어있는 것을 특징으로 하는 방법.
  8. 제5항 내지 7항중 어느항에 있어서, 염화나트륨을 이용하여 완충액의 이온강도를 증가시키는 것을 특징으로 하는 방법.
  9. 제8항에 있어서 염화나트륨의 농도가 a) 단계의 경우는 0.11M이고 b) 단계에서는 0.15M이며 또한 C)단계의 경우는 O.25M인 것을 특징으로 하는 방법.
  10. 제1항 내지 9항중 어느항에 있어서, 화학적 비활성 작용제의 존재하의 혈장성분을 크로마토그래피 존재하의 혈장성분을 크로마토그래피 분리단계로 보내지 직전에 바이러스 비활성 처리하는 갓을 특징으로 하는 방법.
  11. 100 IU/㎎ 이상의 비활성으로 되며, 제2항 내지 1O항중 어느항에 따른 방법으로 형성한 것을 특징으로 하는 단일-그룹 농축물의 특성과 유사한 특성의 제 Ⅷ인자 농축물.
  12. 헤파린-세파로오스 수지에서의 부가적인 크로마토그래피 단계를 거쳐 정제되고 또한 제5항의 방법중 a) 단계의 용리액으로 된 것을 특징으로 하는 피브리노겐 농축물.
  13. a) 단계와 동일한 수지에서의 부가적인 크로마토그래피 단계를 거쳐 정제되고 0.15M의 NaCl로 조절된 완충액으로 용리하며, 또한 제5항의 방법중 b) 단계의 용리액으로 된 것을 특징으로 하는 반빌레브란드 인자 농축물.
  14. 부가적인 겔 여과단계를 거쳐 정제되며 또한 제5항의 방법중 b) 단계의 올리액으로된 것을 특징으로 하는 피브로넥틴 농축물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700239A 1988-06-07 1989-02-08 혈장단백질의 크로마토그래피 분리법 KR970010923B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR88.07503 1988-06-07
FR88.07530 1988-06-07
FR8807530A FR2632309B1 (fr) 1988-06-07 1988-06-07 Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
PCT/FR1989/000050 WO1989012065A1 (fr) 1988-06-07 1989-02-08 Separation chromatographique des proteines du plasma

Publications (2)

Publication Number Publication Date
KR900701823A true KR900701823A (ko) 1990-12-04
KR970010923B1 KR970010923B1 (ko) 1997-07-02

Family

ID=9367001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700239A KR970010923B1 (ko) 1988-06-07 1989-02-08 혈장단백질의 크로마토그래피 분리법

Country Status (17)

Country Link
US (1) US5252709A (ko)
EP (1) EP0359593B2 (ko)
JP (1) JP2805364B2 (ko)
KR (1) KR970010923B1 (ko)
AT (1) ATE121750T1 (ko)
AU (2) AU622436B2 (ko)
CA (1) CA1340742C (ko)
DE (2) DE68922358T3 (ko)
DK (1) DK175322B1 (ko)
ES (1) ES2070919T5 (ko)
FI (1) FI96210C (ko)
FR (1) FR2632309B1 (ko)
LT (1) LT3333B (ko)
NO (1) NO177188C (ko)
RU (1) RU1837880C (ko)
UA (1) UA11061A (ko)
WO (1) WO1989012065A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150090252A (ko) * 2012-12-05 2015-08-05 체에스엘 베링 게엠베하 치료학적 단백질의 정제 방법

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
DE3904354A1 (de) * 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
NL9000090A (nl) * 1990-01-15 1991-08-01 Harimex Ligos Bv Werkwijze voor het bereiden van een fibrinogeenconcentraat uit bloedplasma, inrichting voor het uitvoeren van deze werkwijze en werkwijze voor het bereiden van fibrinogeen uit het concentraat.
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
DE4202667C1 (ko) * 1992-01-29 1993-05-13 Behringwerke Ag, 3550 Marburg, De
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
ES2139227T5 (es) * 1994-07-14 2011-05-04 Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación.
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
EP0910581B1 (de) * 1996-06-24 2000-04-05 Max-Planck-Institut für Physiologische und Klinische Forschung Kerckhoff-Klink GmbH Verfahren zur affinitätschromatographischen aufreinigung von faktor viii
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
DE60035260T2 (de) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
FR2857267B1 (fr) 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
WO2005077528A1 (en) * 2004-02-05 2005-08-25 Millipore Corporation Porous adsorptive or chromatographic media
DE102004009400A1 (de) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
FR2874216B1 (fr) 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
FR2885369B1 (fr) * 2005-05-04 2010-11-12 Lab Francais Du Fractionnement Materiel infectieux synthetique et standardise de type prion et ses utilisations en tant qu'inoculum infectant.
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
US20110065900A1 (en) * 2008-05-30 2011-03-17 Ge Healthcare Bio-Science Ab Separation method utilizing polyallylamine ligands
EP2293776B8 (de) 2008-06-23 2016-05-11 Bio-Products & Bio-Engineering Aktiengesellschaft Lagerstabiles, funktionell intaktes virus-inaktiviertes fibrinogen
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
IT1396528B1 (it) * 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
PL2499165T3 (pl) 2009-11-13 2017-04-28 Grifols Therapeutics Inc. Preparaty zawierające czynnik von willenbranda (vwf) oraz sposoby, zestawy i zastosowania z nim powiązane
FR2952641B1 (fr) 2009-11-18 2012-01-13 Lfb Biomedicaments Procede de traitement du plasma sanguin comprenant une etape de lavage par dispersion
JP6250931B2 (ja) 2010-01-18 2017-12-20 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 血液凝固因子の精製
RU2445974C2 (ru) * 2010-04-26 2012-03-27 Учреждение Российской академии медицинских наук Гематологический научный центр ГНЦ РАМН Способ получения концентрата фактора viii из плазмы крови человека
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
WO2019050321A1 (ko) * 2017-09-07 2019-03-14 (주)프로테옴텍 다수의 검사선을 구비한 크로마토그래피용 스트립, 이를 포함하는 진단 키트 및 다수의 경쟁적 반응 측정 단계를 포함하는 정성, 반정량, 정량 분석방법
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278594A (en) * 1979-06-19 1981-07-14 David Amrani Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma
DK269680A (da) * 1979-06-25 1980-12-26 Rexnord Inc Knivstangsskaerekant med indsnitskonfiguration
US4341764A (en) * 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
FR2570276B1 (fr) * 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
JPS61189228A (ja) * 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
EP0235526A3 (de) * 1986-01-29 1988-03-23 Leipziger Arzneimittelwerk GmbH Aktivierte Polymerfestkörper und Verfahren zu ihrer Herstellung
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates
DE3707213A1 (de) * 1987-03-06 1988-09-15 Behringwerke Ag Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US5097018A (en) * 1988-05-12 1992-03-17 University Of Southern California Sequential heat treatment of blood-clotting factor products
NL8701915A (nl) * 1987-08-14 1989-03-01 Waander Riethorst Adsorbensmateriaal en toepassing daarvan voor het isoleren van stollingsfaktoren.
DE3904354A1 (de) * 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
IT1306645B1 (it) 1999-04-08 2001-10-02 Challenger Gestao E Consultado Struttura di sedia, poltroncina o simile ad assemblaggio facilitato.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150090252A (ko) * 2012-12-05 2015-08-05 체에스엘 베링 게엠베하 치료학적 단백질의 정제 방법
KR20210042422A (ko) * 2012-12-05 2021-04-19 체에스엘 베링 게엠베하 치료학적 단백질의 정제 방법

Also Published As

Publication number Publication date
WO1989012065A1 (fr) 1989-12-14
DE68922358T3 (de) 2004-08-19
FI96210B (fi) 1996-02-15
FI900397A0 (fi) 1990-01-25
AU3068289A (en) 1990-01-05
DE359593T1 (de) 1990-09-27
CA1340742C (fr) 1999-09-14
DE68922358D1 (de) 1995-06-01
NO900529L (no) 1990-04-06
AU622436B2 (en) 1992-04-09
EP0359593A1 (fr) 1990-03-21
NO900529D0 (no) 1990-02-05
RU1837880C (ru) 1993-08-30
NO177188C (no) 1995-08-02
ES2070919T5 (es) 2004-07-16
EP0359593B1 (fr) 1995-04-26
JPH03501974A (ja) 1991-05-09
DK29990A (da) 1990-03-28
JP2805364B2 (ja) 1998-09-30
AU1138392A (en) 1992-05-14
DK175322B1 (da) 2004-08-23
ATE121750T1 (de) 1995-05-15
NO177188B (no) 1995-04-24
KR970010923B1 (ko) 1997-07-02
DE68922358T2 (de) 1995-10-12
DK29990D0 (da) 1990-02-06
FI96210C (fi) 1996-05-27
FR2632309B1 (fr) 1990-08-24
US5252709A (en) 1993-10-12
UA11061A (uk) 1996-12-25
FR2632309A1 (fr) 1989-12-08
LT3333B (en) 1995-07-25
LTIP262A (en) 1994-10-25
ES2070919T3 (es) 1995-06-16
EP0359593B2 (fr) 2004-01-07

Similar Documents

Publication Publication Date Title
KR900701823A (ko) 혈장단백질의 크로마토그래피 분리법
Dunn et al. The α2-Macroglobulin of Human Plasma: I. ISOLATION AND COMPOSITION
US4289689A (en) Preparation of homogeneous human fibroblast interferon
PT1084136E (pt) Separacao de monomeros de anticorpos dos seus multimeros atraves da utilizacao de cromatografia de troca ionica
Perez et al. Enhancement of the chemotactic activity of human C5a des Arg by an anionic polypeptide (" cochemotaxin") in normal serum and plasma.
Van der Westhuyzen et al. Fractionation of chicken erythrocyte whole histone into the six main components by gel exclusion chromatography
Mitsuda et al. Purification of the 11 S component of soybean proteins
KR880003975A (ko) 항응고성 및 항전이성을 갖는 단백질
AU5092685A (en) A preparation for the treatment of hemophilia a inhibitor patients and a process for producing such a preparation
KR840005665A (ko) 면역계에 작용하는 폴리펩티드의 분리 및 정제방법
Schmidt et al. Purification of type E botulinum neurotoxin by high-performance ion exchange chromatography
DE69637464D1 (de) Therapeutische fragmente des "von willebrand" faktors
Isemura et al. Isolation and characterization of glycine-rich gelatin-binding protein, a plasma glycoprotein which interacts with gelatin, arginine, heparin, and hyaluronic acid.
Skinner et al. The separation of collagen α-chains by reversed-phase high-performance liquid chromatography: Comparison of column alkyl stationary phases and temperatures effects
Wagner et al. Ligand exchange amino acid analysis: Resolution of some amino sugars and cysteine derivatives
KR960705841A (ko) 크로마토그래프시키는 방법으로 인자 viii 을 함유하는 바이러스-불활성화된 단편을 제조하는 방법(process for producing a virus-inactivated factor viii-containing fraction by chromatographic methods)
KR890008167A (ko) 인자 viii의 정제에 사용하기 위한 펩타이드 및 그 제조방법
DK0813597T3 (da) Fremgangsmåde til oprensning af vitamin K afhængige koaguleringsfaktorer ved kromatografi
McGregor et al. Tandem separation of labelled human blood platelet membrane glycoproteins by anion-exchange and gel fast protein liquid chromatography
Leaback et al. A new procedure for the two-dimensional display of the molecular size-electric charge characteristics of native proteins in crude mixtures
Appel et al. Application of hydroxyapatite chromatography to alkaline myosin solutions
Wong et al. High-performance liquid chromatography of proteins: Purification of α-fetoprotein from fetal calf serum
Dempfle et al. Isolation and purification of fibrinogen/fibrin degradation products by chromatography on protamine-agarose
Litwiller et al. Identification and isolation of vitamin K-dependent proteins by HPLC
DE69415664D1 (de) Methode zur trennung von glykosylierten und unglykosylierten proteinen

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090716

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee